Literature DB >> 19383976

Immune regulation by rapamycin: moving beyond T cells.

Matthew R Janes1, David A Fruman.   

Abstract

The mammalian target of rapamycin (mTOR) is a multifunctional kinase that promotes cell growth and division in response to growth factor and nutrient signals. Rapamycin exerts its potent immunosuppressive effects in part through direct effects on antigen-specific lymphocytes; however, rapamycin also modulates adaptive immunity through its effects on innate immune cells, including dendritic cells and macrophages. Studies have established rapamycin-sensitive functions of mTOR, downstream of Toll-like receptors, in shaping the cytokine response of myeloid cells and driving the production of interferon by plasmacytoid dendritic cells. These findings point to new strategies for boosting or suppressing specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383976     DOI: 10.1126/scisignal.267pe25

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  21 in total

1.  Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.

Authors:  Xiaolun Sun; Kathryn Winglee; Raad Z Gharaibeh; Josee Gauthier; Zhen He; Prabhanshu Tripathi; Dorina Avram; Steven Bruner; Anthony Fodor; Christian Jobin
Journal:  Gastroenterology       Date:  2018-02-01       Impact factor: 22.682

2.  Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.

Authors:  Ruchi Rastogi; Zhongliang Jiang; Nisar Ahmad; Rita Rosati; Yusen Liu; Laurent Beuret; Robert Monks; Jean Charron; Morris J Birnbaum; Lobelia Samavati
Journal:  J Biol Chem       Date:  2013-10-14       Impact factor: 5.157

Review 3.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

4.  Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling.

Authors:  Smita Majumder; Antonella Caccamo; David X Medina; Adriana D Benavides; Martin A Javors; Ellen Kraig; Randy Strong; Arlan Richardson; Salvatore Oddo
Journal:  Aging Cell       Date:  2012-02-01       Impact factor: 9.304

5.  A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

Authors:  Ellen Kraig; Leslie A Linehan; Hanyu Liang; Terry Q Romo; Qianqian Liu; Yubo Wu; Adriana D Benavides; Tyler J Curiel; Martin A Javors; Nicolas Musi; Laura Chiodo; Wouter Koek; Jonathan A L Gelfond; Dean L Kellogg
Journal:  Exp Gerontol       Date:  2018-02-03       Impact factor: 4.032

Review 6.  Regulation of immune responses by mTOR.

Authors:  Jonathan D Powell; Kristen N Pollizzi; Emily B Heikamp; Maureen R Horton
Journal:  Annu Rev Immunol       Date:  2011-11-29       Impact factor: 28.527

7.  Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling.

Authors:  Xiaolun Sun; Deborah Threadgill; Christian Jobin
Journal:  Gastroenterology       Date:  2011-10-01       Impact factor: 22.682

8.  Targeting TOR dependence in cancer.

Authors:  Matthew R Janes; David A Fruman
Journal:  Oncotarget       Date:  2010-05

9.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors:  Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal:  Nat Med       Date:  2010-01-13       Impact factor: 53.440

10.  p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Authors:  Karl Katholnig; Christopher C Kaltenecker; Hiroko Hayakawa; Margit Rosner; Caroline Lassnig; Gerhard J Zlabinger; Matthias Gaestel; Mathias Müller; Markus Hengstschläger; Walter H Hörl; Jin Mo Park; Marcus D Säemann; Thomas Weichhart
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.